Articles

The Vaccines Manufacturing and Innovation Centre (VMIC) has chosen Lonza’s MODA-EM solution for the digitalization of its microbiology quality control operations.

VMIC Adopts Lonza’s Paperless Quality Control Microbiology Platform

The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have published a joint strategy for medicines regulation in Europe over the next five years.

EMA and HMA Publish Joint Strategy for Medicines Regulation to 2025

With the acquisition, Evonik will expand its life science division and its portfolio of functional excipients and biomaterials. 

Evonik to Acquire Birmingham-Based LACTEL Absorbable Polymers from DURECT Corporation

Evonik offers lipid nanoparticles for gene-based drug development and manufacturing. 

Evonik Supplies Key LNP Technology for Gene-Based Drugs

The European Medicines Agency has launched a full investigation into a cyberattack. 

EMA Launches Investigation into Cyberattack

The company is investing in expansion at four sites in the United States, United Kingdom, and Italy, which will include construction of new facilities and addition of sterile and lyophilized filling lines.

Thermo Fisher Scientific Expands Sterile Drug Product Development and Commercial Manufacturing

The collaboration includes the development, commercialization, and supply of Orgenesis’ pipeline in South Korea and Japan and the development and commercialization of Cure Therapeutics’ pipeline on a global basis.

Orgenesis and Cure Therapeutics Form Joint Venture for Cell and Gene Therapies

Cytiva is adding process development, media and assay development, and contract development services at its facilities in Korea, Japan, Sweden, and the UK.

Cytiva Expands Cell and Gene Therapy Fast Trak Services

Through the acquisition, PTI will gain access to LDA’s lead product, the SIMS 1915+, a helium leak test system that combines its helium leak detection technology with its SIMS software for data collection and analysis.

PTI Completes Acquisition of LDA

The company has received $500 million in funding from Sino Biopharmaceutical for further development, capacity expansion, and manufacturing of CoronaVac, its COVID-19 vaccine candidate.

News